(Q54505356)

30 May 2018

title

Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients. (English)

1 reference

30 May 2018

1 reference

acute myeloid leukemia

1 reference

6

Hagop M Kantarjian

1 reference

30 May 2018

4

Farhad Ravandi

1 reference

30 May 2018

5

Jorge E Cortes

1 reference

30 May 2018

3

C Cameron Yin

1 reference

30 May 2018

Rajyalakshmi Luthra

2

object named as

Rajyalakshmi Luthra

1 reference

30 May 2018

L Jeffrey Medeiros

7

object named as

L Jeffrey Medeiros

1 reference

30 May 2018

author name string

Mikako Warren

1

1 reference

30 May 2018

Zhuang Zuo

8

1 reference

30 May 2018

publication date

8 June 2012

1 reference

30 May 2018

published in

Modern Pathology

1 reference

30 May 2018

volume

25

1 reference

30 May 2018

issue

10

1 reference

30 May 2018

page(s)

1405-1412

1 reference

30 May 2018

The roles of FLT3 in hematopoiesis and leukemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Will newer tyrosine kinase inhibitors have an impact in AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

FLT3/ITD AML and the law of unintended consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

Acquired isodisomy for chromosome 13 is common in AML, and associated with FLT3-itd mutations

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.88

7 January 2021

10.1038/MODPATHOL.2012.88

Identifiers

DOI

1 reference

30 May 2018

Dimensions Publication ID

1020699558

0 references

1 reference

30 May 2018